Evolus/EOLS

$13.72

4.25%
-
1D1W1MYTD1YMAX

About Evolus

Evolus, Inc. is a performance beauty company, which is focused on delivering products in the self-pay aesthetic market. Its first commercial product is Jeuveau, which is a 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the self-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications that are not reimbursed by any third-party payor, such as Medicaid, Medicare or commercial insurance. Jeuveau is manufactured using Hi-Pure technology. The Company commercially launched Jeuveau in the United States. The Company manufactures both Jeuveau and BOTOX. BOTOX (onabotulinumtoxinA) is the neurotoxin approved 900 kDa botulinum toxin type A complex in the United States.
Ticker
EOLS
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
David Moatazedi
Employees
246
Headquarters
Newport beach, United States

Evolus Metrics

BasicAdvanced
$792.48M
Market cap
-
P/E ratio
-$1.11
EPS
1.44
Beta
-
Dividend rate

What the Analysts think about Evolus

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
57.22% upside
High $27.00
Low $16.00
$13.72
Current price
$21.57
Average price target

Evolus Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-33.8% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$50M
1.42%
Net income
$-16.9M
-6.63%
Profit margin
-33.8%
-7.93%

Evolus Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.05%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.14
-$0.15
-$0.19
-$0.16
-
Expected
-$0.15
-$0.15
-$0.19
-$0.17
-$0.07
Surprise
-5.28%
1.12%
-2.26%
-8.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Evolus stock

Buy or sell Evolus stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing